News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat [Yahoo! Finance]
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Yahoo! Finance
NASDAQ:PTGX ), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business. At US$37.59, shares are up 4.4% in the past 7 days. Investors could be forgiven for changing their mind on the business following the downgrade; but it's not clear if the revised forecasts will lead to selling activity. Following the downgrade, the consensus from ten analysts covering Protagonist Therapeutics is for revenues of US$94m in 2025, implying a concerning 78% decline in sales compared to the last 12 months. Following this this downgrade, earnings are now expected to tip over into loss-making territory, with the analysts forecasting losses of US$1.20 per share in 2025. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$128m and losses of US$1.02 per share in 2025. Er
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- Protagonist Therapeutics (NASDAQ:PTGX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
- Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.MarketBeat
- Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $81.00. They now have an "overweight" rating on the stock.MarketBeat
PTGX
Earnings
- 11/6/25 - Miss
PTGX
Sec Filings
- 11/24/25 - Form 4
- 11/19/25 - Form 4
- 11/14/25 - Form SCHEDULE
- PTGX's page on the SEC website